摘要
目的探讨吡格列酮与沙格列汀治疗二甲双胍治疗效果不佳的肥胖型2型糖尿病的效果。方法根据计算机随机生成数字表将我院收治的74例二甲双胍治疗效果不佳的肥胖型2型糖尿病患者分为研究组和对照组,各37例。两组患者均给予基础治疗措施及二甲双胍治疗。在此基础上,对照组给予吡格列酮治疗,研究组给予沙格列汀治疗。比较两组患者的治疗效果。结果治疗后,两组的FPG、2hPPG、FFA水平均降低,2hPCP、APOL及HDL-C水平均升高,且研究组优于对照组(P<0.05)。治疗后,两组的8-OHdG水平及体重均降低,且研究组低于对照组(P<0.05)。研究组的并发症总发生率低于对照组(P<0.05)。结论与吡格列酮比较,沙格列汀治疗二甲双胍治疗效果不佳的肥胖型2型糖尿病的效果显著,其可有效改善患者糖脂代谢水平,控制患者体重,值得临床推广应用。
Objective To investigate the effects of pioglitazone and sagliptin in the treatment of obesity type 2 diabetes mellitus with poor efficacy of metformin. Methods According to the computer generated digital table, 74 patients with obesity type 2 diabetes mellitus with poor efficacy of metformin in our hospital were divided into study group and control group, with 37 cases in each group. Both groups given basic treatment and metformin treatment, on this basis, the control group was treated with pioglitazone, and the study group was treated with sagliptin. The therapeutic effects of the two groups were compared. Results After treatment, the levels of FPG, 2 h PPG and FFA in both groups decreased, while the levels of 2 h PCP, APOL and HDL-C in both groups increased, and those in the study group were better than the control group (P<0.05). After treatment, the levels of 8-OHdG and body weight in both groups decreased, and those in the study group were lower than the control group (P<0.05). The total incidence of complications in the study group was lower than that in the control group (P<0.05). Conclusion Compared with pioglitazone, the sagliptin in the treatment of obesity type 2 diabetes mellitus with poor efficacy of metformin has remarkable effect. It can effectively improve the level of glycolipid metabolism and control the weight of patients, which is worthy of clinical promotion and application.
作者
郑长余
ZHENG Chang-yu(the Hospital of Mian County, Hanzhong 724200, China)
出处
《临床医学研究与实践》
2019年第18期3-5,共3页
Clinical Research and Practice
关键词
吡格列酮
沙格列汀
2型糖尿病
肥胖
pioglitazone
sagliptin
type 2 diabetes mellitus
obesity
